Exploring Integer Holdings Corporation (ITGR) Investor Profile: Who’s Buying and Why?

You're looking at Integer Holdings Corporation (ITGR) and asking the right question: who is buying this stock, and why are they stepping in when the price has been so volatile? Honestly, the investor profile is a classic institutional tug-of-war right now. We know that institutional ownership is overwhelmingly high, sitting near 97.79%, with giants like BlackRock, Inc. holding a significant stake-over 5.1 million shares, or about 14.70% of the company, as of mid-2025. But here's the rub: despite the company delivering a strong Q3 2025 with adjusted EPS up 25% to $1.79, the stock price had plummeted around 37% in late October 2025 due to a soft 2026 outlook. So, are the big players selling off, or are value investors seeing a deep discount? The recent open-market purchase of 3,127 shares by the CEO-elect for over $203,000 is a clear vote of insider confidence, but it's a drop in the bucket against the full-year 2025 sales forecast of $1.84 billion to $1.854 billion. We need to look past the headline drop and see which institutional types are rotating out and which are doubling down on the long-term thesis-the one built on a projected 2025 adjusted EPS of up to $6.43. Let's unpack the filings and figure out if this is a falling knife or a rare buying opportunity.

Who Invests in Integer Holdings Corporation (ITGR) and Why?

You're looking at Integer Holdings Corporation (ITGR), and the question isn't just about the medical device contract development and manufacturing organization (CDMO) business model, but who's betting on it. The direct takeaway is that ITGR is overwhelmingly an institutional play, with nearly all of the float held by major funds who are primarily motivated by the company's strong, specialized growth in the Cardio & Vascular segment and a compelling valuation in late 2025.

The ownership structure is heavily skewed toward professional money managers. As of late 2025, institutional investors hold a dominant position, accounting for roughly 81.39% of the company's stock, with some metrics pushing that figure even higher. This is a stock where the big players-the mutual funds, pension funds, and hedge funds-drive the price action, not retail sentiment. About 749 institutions have reported holding shares.

The remaining ownership is split between retail investors, who hold around 17.76%, and company insiders, who own a small but crucial 0.85% to 2.21%. Insiders have been active in late 2025, with both buying (CEO, Director) and selling (VP) noted, which is a mixed signal, but the institutional weight is what matters most here.

Key Investor Types and Their Footprint

When you peel back the layers, you see three distinct groups, each with a different approach to Integer Holdings Corporation.

• Institutional Giants: Passive, long-term holders like BlackRock, Inc. and Vanguard Group Inc. are the largest shareholders. They own ITGR because it's a component of major indices (like the S&P SmallCap ETF) and fits their long-term sector allocation to the stable, growing medical device market.
• Hedge Funds: These are the active, tactical players. Firms like Viking Global Investors LP hold significant positions, but their activity is mixed, indicating they are actively managing their exposure based on near-term catalysts. For instance, in Q3 2025, you saw some funds reducing their stake by over 20%, while others were initiating or increasing positions.
• Retail and Individual Investors: This group is the minority, often following the lead of institutional sentiment or attracted by the company's strong fundamentals. Their smaller positions don't move the stock much, but they represent the remaining float.

Investment Motivations: Growth and Value

The primary attraction to Integer Holdings Corporation in 2025 is a compelling mix of growth and value, especially for a company in the defensive healthcare sector. It's defintely not a dividend play, as the company does not pay one.

The growth story is clear: Integer Holdings Corporation is a leader in a critical niche-making the components for complex medical devices. Their Q3 2025 results showed sales climbing 8% year-over-year, with organic growth at 7%. The Cardio & Vascular segment is a powerhouse, jumping 24% in Q2 2025, driven by new product ramps in electrophysiology and neurovascular. That's a huge number for a mature CDMO.

Here's the quick math on the value proposition: The company's full-year 2025 adjusted earnings per share (EPS) guidance is tight, between $6.29 and $6.43. With a forward price-to-earnings (P/E) ratio of around 11.02 in November 2025, the stock looks cheap relative to the broader market, which is why value investors are circling.

Plus, the Board's authorization of a $200 million share repurchase program on November 4, 2025, is a massive vote of confidence. Management is signaling they believe the stock is undervalued, and they're willing to put capital to work to prove it. This is a classic value catalyst. You can learn more about how the company got to this point here: Integer Holdings Corporation (ITGR): History, Ownership, Mission, How It Works & Makes Money.

Investment Strategies in Play

The investor profile suggests a blend of strategies are at work, which creates a dynamic trading environment.

What this estimate hides is the leverage ratio. The company's total debt rose to $1.194 billion in Q3 2025, pushing the leverage ratio to 3.0x adjusted EBITDA. While this is within their target, it's a key risk that active investors, particularly hedge funds, are watching closely and likely explains some of the recent selling activity. The low P/E might be a value trap if that debt load becomes a problem, so you need to keep a close eye on free cash flow generation.

The next concrete step for you is to model the impact of the $200 million buyback on the share count and the resulting EPS increase for 2026, assuming the buyback is executed at the current price levels.

Institutional Ownership and Major Shareholders of Integer Holdings Corporation (ITGR)

You're looking at Integer Holdings Corporation (ITGR), a leading medical device contract development and manufacturing organization, and the first thing to grasp is that this is defintely an institutionally-dominated stock. It's not a retail playground. As of late 2025, institutional investors-the big funds, pension plans, and endowments-own an overwhelming majority of the company, with ownership figures ranging from 99.29% to over 116.14% of the float, depending on how you account for all the different financial instruments they hold.

This high concentration means that the movements and decisions of a few very large players dictate the stock's trajectory, far more than any individual investor's activity. When these whales move, the stock price feels it. The institutional value of their long positions alone totaled over $6.04 billion.

Top Institutional Investors: Who Holds the Keys?

When you peel back the layers on ITGR's shareholder base, you find the usual suspects from the world of massive asset management, plus a few key hedge funds taking significant stakes. The largest single holder is Tudor Investment Corp Et Al, which holds a disproportionately large position, signaling a high-conviction bet on the company's long-term value in the medical device outsource manufacturing space.

Here's the quick math on the top holders, based on the most recent 2025 filings, which shows just how concentrated the ownership is among the top five:

What this table hides is the fact that Tudor Investment Corp Et Al's position is highly unusual for a public company, which suggests a unique, potentially activist, or legacy investment structure. Still, the presence of passive giants like Blackrock Inc. and Vanguard Group Inc. means a significant portion of the stock is held in index funds, providing a stable, long-term floor for the price.

Recent Shifts: Institutional Buying and Selling

The institutional landscape for Integer Holdings Corporation has been dynamic in 2025, with a near-even split of buyers and sellers in the most recent quarter: 180 institutions added shares, and 170 decreased their positions. This tells you there's a real debate happening on Wall Street about the stock's current valuation and future growth.

We've seen some aggressive accumulation, which often signals confidence in the company's strategic direction, especially after the appointment of a new CEO in April 2025.

• Massachusetts Financial Services Co added 405,861 shares in Q3 2025, valued at over $41.9 million.
• Alliancebernstein L.P. significantly boosted its stake, adding 993,810 shares, an increase of 885.1%, in Q2 2025.
• Artisan Partners Limited Partnership raised its holdings by 31.7% in Q2 2025, purchasing an additional 53,114 shares.

But it's not all buying. Some large funds are taking profits or reallocating capital, which is a key risk to monitor. For instance, Capital Research Global Investors removed a massive 1,342,493 shares in Q2 2025, a 96.4% reduction in their holding. Vaughan Nelson Investment Management, L.P. also completely exited its position, removing 282,485 shares.

Impact on Stock Price and Strategy

Institutional investors play a crucial role in Integer Holdings Corporation's stock price and corporate strategy, especially given the stock's significant decline of 49.54% from November 2024 to November 2025, trading at around $68.04 per share.

Their collective pressure and conviction are what drive major corporate finance decisions. A clear example is the board's authorization of a $200.00 million share repurchase program in November 2025, which allows the company to reacquire up to 8.3% of its stock. This is a direct signal to the market-and to institutional holders-that management believes the stock is undervalued, a move often demanded by large, capital-efficient investors.

These investors are also keenly focused on the financial guidance. The company's FY 2025 guidance projects earnings per share (EPS) in the range of $6.290 to $6.430, which is the benchmark against which institutional performance is measured. They expect management to execute on the strategic initiatives, including the major acquisition made earlier in 2025, to justify their large positions. If you want to understand the core mission driving these decisions, you should review the company's guiding principles: Mission Statement, Vision, & Core Values of Integer Holdings Corporation (ITGR).

The action for you is to monitor the next round of 13F filings closely to see if the net buying trend continues, especially from the high-conviction hedge funds, which would signal a bottoming of the stock price after the recent volatility. Finance: track Q4 2025 13F filings for Blackrock Inc. and Vanguard Group Inc. by the February 2026 deadline.

Key Investors and Their Impact on Integer Holdings Corporation (ITGR)

If you're looking at Integer Holdings Corporation (ITGR), the first thing you need to understand is that this is an institutionally-driven stock. This isn't a retail-heavy name; the big money controls the narrative. Institutional investors-meaning mutual funds, pension funds, and asset managers-hold the vast majority of the company's shares.

As of the most recent filings, institutional ownership hovers around a staggering 81.39% of the outstanding stock. That's a huge concentration of capital, and it means that a few major players have a defintely outsized say in the company's long-term strategy and short-term stock movements. For a deeper dive into the company's foundation, you can check out Integer Holdings Corporation (ITGR): History, Ownership, Mission, How It Works & Makes Money.

The Giants Driving the Integer Holdings Corporation Stock

The top holders are exactly who you'd expect to see in a mid-cap medical device contract development and manufacturing organization (CDMO) like Integer Holdings Corporation. These are the passive index giants and the massive active asset managers. They buy in size because the company is a core holding in the healthcare and small-cap indexes they track.

The sheer volume of their holdings means their trading activity-even routine rebalancing-can move the stock price. Here's the quick math on the largest stakes based on 2025 fiscal year data:

Vanguard Group Inc. and BlackRock, Inc. alone control over a quarter of the company. When you see names like that, you know the investment thesis is largely tied to long-term sector growth and inclusion in major exchange-traded funds (ETFs) and mutual funds.

Recent Moves: Share Buybacks and Insider Selling

In the near-term, investor action has been mixed, but the company itself has made a clear capital allocation move. On November 4, 2025, the Board of Directors authorized a new share repurchase program of up to $200 million of common stock. This is a direct signal to the market that management and the Board believe the stock is undervalued, and it's a tangible way to boost earnings per share (EPS).

• The repurchase authorization covers up to $200 million, which is a significant chunk of capital.
• Artisan Partners Limited Partnership, a major fund, increased its holdings by 31.7% in the second quarter of 2025, buying an additional 53,114 shares.
• Conversely, some company insiders, including VP Tommy P. Thomas and John A Harris, executed sales in November 2025, totaling over $177,000 in value.

What this estimate hides is the context: institutional buying signals confidence, but insider selling, even if small in scale, can raise eyebrows right after a major stock price drop.

Investor Influence: The Guidance Shock

The most recent and potent example of investor influence came right after the Q3 2025 earnings report on October 23, 2025. Integer Holdings Corporation reported strong third-quarter results with an adjusted EPS of $1.79 on revenue of $468 million. Honestly, those numbers beat analyst expectations.

But, the stock plummeted anyway, dropping a massive 37.16% in the immediate aftermath. Why? Because the company's preliminary outlook for 2026 showed potential headwinds, including challenges in the electrophysiology and neuromodulation product lines. This is a classic case of institutional investors prioritizing future guidance (the outlook) over past performance (the Q3 beat). The market's reaction was swift and brutal; they are clearly focused on the company's ability to maintain its growth trajectory in the medical device space.

Actionable next step: Portfolio Managers should model the impact of the $200 million share repurchase on 2026 EPS by the end of the quarter.

Market Impact and Investor Sentiment

You are looking at Integer Holdings Corporation (ITGR) right now, and the investor sentiment is a textbook example of short-term pain versus long-term conviction. The current view is best described as cautiously positive, but with a major caveat: the market is focused on a near-term hiccup, not the underlying business strength.

The company's Board authorized a $200 million share repurchase program on November 4, 2025, which is a powerful signal. When management uses cash on hand and free cash flow for a buyback, they are defintely saying the stock is undervalued. This action reinforces confidence in the company's strategy and financial position, despite the anticipated challenges in 2026. That's a strong vote of confidence from the top.

• Institutional investors own 99.29% of the stock.
• Vanguard Group Inc. holds a significant position of 3,871,685 shares.
• The buyback is a potential stock support catalyst.

Recent Market Reactions and the 2026 Headwind

The market's reaction to Integer Holdings Corporation's Q3 2025 results was swift and brutal, even though the quarter itself was strong. The stock plummeted a staggering 37.16% to close at approximately $68.56 around the time of the October 2025 earnings release.

Here's the quick math on the investor panic: Q3 adjusted earnings per share (EPS) surged 25% year-over-year to $1.79, beating analyst consensus. But, the forward-looking guidance for 2026, which projects a 'digestion year' due to lower-than-expected adoption of three new products (two in electrophysiology and one in neuromodulation), spooked the market. Investors hate uncertainty, so they sold first. The CEO-elect, Payman Khales, addressed this unusual situation, emphasizing it is not expected to be a recurring issue, but still, the stock took a hit.

Analyst Perspectives: Mapping the Opportunity

The analyst community remains broadly supportive, which is a key divergence from the immediate market reaction. The consensus among Wall Street analysts covering Integer Holdings Corporation is a Buy rating. Specifically, three out of six analysts are recommending a Strong Buy.

This positive outlook is grounded in the company's robust 2025 performance and the long-term view of its strategic positioning in high-growth medical device markets like interventional cardiology and neuromodulation. The average analyst price target is approximately $84.86, suggesting a potential upside of over 22% from the current November 2025 stock price. They see the 2026 slowdown as a temporary reset before the company returns to above-market organic growth in 2027. You can see their confidence in the long-term strategy, which is detailed further in the Mission Statement, Vision, & Core Values of Integer Holdings Corporation (ITGR).

What this estimate hides is the potential for the 2026 headwinds to be less severe than currently guided, which would send the stock higher quickly. But for now, you should plan for the guided numbers.

Finance: Track institutional ownership changes for Vanguard Group Inc. and other major holders in the next 13F filings to confirm their conviction levels have not materially changed by the end of the year.